Dermorphin: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides โ
๐TL;DR
- โขCommunity protocols detailed below
- โขEvidence level: Anecdotal Reports
- โขSee community reports below
- โขStacking patterns detailed below
Sources
- Reddit r/Peptides|Dermorphin discussions and opioid peptide safety concerns(accessed 2026-02-16)
- Wikipedia|Dermorphin overview including horse racing doping controversy(accessed 2026-02-16)
- Paulick Report|NHBPA statement on dermorphin use in horse racing(accessed 2026-02-16)
Community Evidence Overview#
This page documents the community evidence landscape for dermorphin. This is not clinical evidence and should not be used as medical guidance.
Dermorphin has no legitimate self-experimenter community and no community-sourced protocols. This peptide is a potent opioid agonist that exists in the research and regulatory context, not the peptide self-experimentation community.
Why There Are No Community Protocols#
Dermorphin is a naturally occurring opioid heptapeptide isolated from frog skin that is 30-40 times more potent than morphine at the mu-opioid receptor. Several factors preclude any legitimate community use:
Safety Concerns#
- Extreme potency: At 30-40x the potency of morphine, dosing errors carry a high risk of fatal respiratory depression
- Addiction liability: As a potent mu-opioid agonist, dermorphin carries significant addiction potential
- No human safety data: Dermorphin has never undergone human clinical trials to establish safe dose ranges
- No antidote specificity: While naloxone may reverse effects, the potency and pharmacokinetics of dermorphin create unpredictable emergency scenarios
Regulatory Status#
Dermorphin is not scheduled as a controlled substance in most jurisdictions because it is classified as a research chemical. However, it is classified as a Class I prohibited substance by the Association of Racing Commissioners International (ARCI) due to its documented misuse in horse racing doping.
Horse Racing Doping Context#
Dermorphin gained public attention through its detection in equine doping. Starting around 2011, approximately 30 positive tests were identified at racetracks in Oklahoma and Louisiana. Horses were reportedly administered dermorphin intravenously shortly before post time to produce opioid-mediated effects. Advanced LC-MS/MS detection methods were subsequently developed to test for dermorphin and 17 related peptide analogs in equine samples.
Research Context#
Dermorphin remains a valuable research tool for studying opioid receptor pharmacology, receptor binding selectivity, and the structure-activity relationships of opioid peptides. Its unusual D-alanine residue at position 2 provides resistance to enzymatic degradation, making it useful for studying prolonged opioid receptor activation in laboratory settings.
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About Dermorphin
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.